UK Reports A Subtle Surge In Yeast Infections: Report

New figures from the UK Health Security Agency (UKHSA) show that bloodstream infections caused by yeast continue to be a growing concern. In 2024, these infections increased by 4% compared to 2023, rising from 2,170 to 2,247 cases. This translates to an infection rate of 3.9 per 100,000 people across England, up from 3.8 the previous year.

How Yeast Enters the Bloodstream

Bloodstream infections caused by yeast often occur in hospital settings. These infections are typically linked to yeasts naturally present on our skin or in the gut. When patients receive prolonged courses of broad-spectrum antibiotics, their normal bacterial flora is suppressed, allowing yeasts to grow unchecked. In some cases, these yeasts can cross the gut wall and enter the bloodstream. Individuals with weakened immune systems—such as cancer patients or those using invasive medical devices—are particularly vulnerable.

Most Common Yeast Species Behind Infections

The leading cause of yeast bloodstream infections remains Candida albicans, followed by Nakaseomyces glabratus (formerly Candida glabrata) and Candida parapsilosis. Interestingly, N. glabratus infections were most common among the elderly, while C. albicans and C. parapsilosis infections were more frequent in children.

Infection Rates Higher in Deprived Areas

The UKHSA report highlights a concerning disparity in infection rates across socioeconomic groups. In 2024, people living in the most deprived parts of the country experienced higher rates of bloodstream yeast infections (5.0 per 100,000) compared to those in the least deprived areas (3.2 per 100,000). UKHSA is currently working with healthcare partners to better understand these differences.

The Rise of Drug-Resistant Candidozyma auris

While resistance to antifungal drugs overall has remained stable, the rise of Candidozyma auris (previously Candida auris) is raising alarm. This drug-resistant fungus has emerged as a significant global health threat. Between 2013 and 2024, England recorded 637 cases of C. auris, with 178 of them reported in 2024 alone. Most notably, cases surged following the end of COVID-related travel restrictions.

To support healthcare providers, UKHSA has issued updated guidance for managing C. auris outbreaks. The fungus is now a notifiable disease, meaning all confirmed cases must be reported to public health authorities.

Ongoing Surveillance and the Need for Vigilance

Professor Andy Borman, Head of the Mycology Reference Laboratory at UKHSA, emphasized the growing impact of serious fungal infections on public health. He noted that increasing numbers of immunocompromised patients and complex medical treatments may be contributing to the rise.

Although antifungal drugs remain effective for now, that could change if resistance grows. “The rise of drug-resistant C. auris in hospitals means we must remain vigilant,” said Borman, stressing the importance of infection control and improved surveillance.

Unlike bacterial infections, fungal infections did not decline during the pandemic, likely due to overwhelmed hospital systems and complications from severe COVID-19. As infection rates continue to climb, rapid diagnostics and better tools for managing these infections remain a public health priority.